Mediclinic International Plc (MDC) 2019年年度报告「LSE」.pdf

1、2019ANNUALREPORTCONTENTS4At a glanceSTRATEGIC REPORTBusiness overview10Performance summary 12Chairmans Statement16Business model18Our strategy,goals and progress22Investment case23Five-year summaryPerformance and future outlook24Chief Executive Officers Review29Financial Review40Value added statemen

2、t41Clinical services overviewRisk management55Risk management,principal risks and uncertainties60Viability statementDivisional reviews62Divisional Review Switzerland67Divisional Review Southern Africa71Divisional Review UAENon-financial performance76Sustainable development overview100Non-financial i

3、nformation statementGOVERNANCE AND REMUNERATION103Chairmans Introduction104Board of Directors110Group Executive Committee114Corporate Governance Statement136Audit and Risk Committee Report150Clinical Performance and Sustainability Committee Report154Nomination Committee Report159Directors Remunerati

4、on Report179Statement of Directors ResponsibilitiesFINANCIAL STATEMENTS182Group Financial Statements280Company Financial StatementsADDITIONAL INFORMATION296Shareholder information300Company information302Forward-looking statements303GlossaryMEDICLINIC INTERNATIONAL PLC|2019 ANNUAL REPORT 1OVERVIEWAD

5、APTING MEDICLINIC TO THE CHANGING GLOBAL HEALTHCARE ENVIRONMENTis a priority with focus throughout the Group to invest across the continuum of care750 000 INPATIENT ADMISSIONSacross the Group as the demand for quality healthcare services remains strong232M SIGNIFICANT ONGOING INVESTMENT across the G

6、roup supporting patient experience,clinical excellence,maintenance,upgrades and expansionREVENUE UP 2%to 2 932m;up 4%in constant currencyADJUSTED EBITDA DOWN4%to 493m;down 2%in constant currency reflecting the financial impact of regulatory changes on Hirslanden LOSS OF151M*impacted by non-cash Hirs